Buprenorphine-naloxone (Suboxone®): What’s new?
|
Satellite Meeting at Harm Reduction 2008: IHRA’s 19th International Conference
Barcelona, Spain
|
Sunday May 11th 2008
13.15-15.30
|
Click here to view the satellite programme [PDF:12KB]
|
Introduction
|
Medically assisted treatment for opioid dependence – with methadone or buprenorphine - is available in an increasing number of countries. Buprenorphine (‘Subutex’) has had a significant impact worldwide in reducing the harms associated with opioid dependence and injecting and in expanding access to safe and effective treatment in a variety of treatment settings. Like all opioid treatment medications, buprenorphine treatment has been associated with some misuse (such as injection) and diversion. The combination tablet formulation of buprenorphine containing buprenorphine plus naloxone (‘Suboxone’) in a 4:1 ratio was developed to reduce buprenorphine misuse while maintaining all of the benefits of this therapy for opioid dependence. Suboxone is currently available in the USA, Australia, New Zealand, Malaysia, Canada and various countries across Europe.
|
What’s new and what is the evidence?
|
There has been considerable debate and discussion about buprenorphine plus naloxone (Suboxone). This session will highlight the current evidence on its use. It will include the latest post-marketing surveillance and laboratory data with Suboxone available from the USA, Australia, and France.
• Dr Charles R. Schuster (USA) will discuss current findings from the U.S. post marketing study
• Dr Louisa Degenhardt and Dr Briony Larance (Australia) will share the results of the Australian post-marketing research
• Dr Jean-Pierre Daulouede (France) will present laboratory findings on the preference for Subutex and Suboxone among patients taking buprenorphine
• Dr Sandra Comer (USA) will present laboratory findings on the comparative liability to inject buprenorphine-naloxone and buprenorphine alone in buprenorphine-maintained individuals
Overall, with Professor Marc Auriacombe (France) as chair, and with Professor John Strang (UK) as discussant, participants will become familiar with the latest data on buprenorphine-naloxone, including this formulation’s potential for the treatment of opioid dependence.
This session will be of interest to a wide range of conference participants including clinicians, service providers, patients, and people planning and commissioning treatment services.
|
Click here to view the satellite programme [PDF:12KB]
|
Registration
|
Participation in this satellite event is free, but delegates are urged to register now to secure a place.
|
To register your advance interest in this satellite and ensure a place please email Annie Kuch.
|
Please note that lunch will not be provided.
This session is supported by an unrestricted educational grant from Schering-Plough.
|
